INS and Hypoglycemia: To our knowledge, this study represents the first case-series report from Taiwan that evaluates the real-world clinical benefits of switching Taiwanese diabetes patients from Gla-100 to Gla-300 for basal insulin therapy with regard to glucose variability minimization and nocturnal hypoglycemia reduction by means of CGM.